Previously, we have shown that immunization with human papillomavirus (HPV) type 16-derived cytotoxic T lymphocyte (CTL) epitope E7 <W-57 (RAHYNIVTF) renders C?7BL/6mice insensitive to tumors formed hy HPV16-transformed cells. In this study, we provide evidence that E7 49-57 is expressed as a subdominanl CTL epitope on HPVI6-transformed C57BL/6 cells. Using acid peptide cliilion, it is shown that HPV16-transformed tells express another CTL epitope. besides E7 49-57, which appears to he dominant. We demonstrate that a CTL line raised against the subdominant CTL epitope. offered as synthetic peptide E7 49-57, eradicates established. HPV16-mduced tumors in mice. Our data show that synthetic peptide-induced CTL can be applied successfully in vivo against (virus-induced) tumor, and emphasize thai subdominant CTL epitopes are useful targets for immunothcrapy. Furthermore, it is illustrated for the first time that HPV In-specific CTL interfere directly with HPVIft-indueed tumors.
Introduction
Human papillomavirus (HPV) type 16, in particular the Viral oncogene products E6 and È7, arc believed to piuy a causative role in cervical cancer flj, Development of HPV16-associated (pre)malignant lesions is enhanced in individuals with impaired T ceJI responses J2-5J, suggesting that cellular immunity impedes HPV Ift-associated tumor development, CTL are important effectors of protection against (virus-induced) cancer [6, 7|. They lyse target cells upon recognition of specific peptides presented at the cell surface by MHC class 1 molecules |8j. In the case of virus-infected cefls, these peptides originate mainly from rntraceJlular viral proteins [9, 10J, which are degraded in the cylosol and bound specificaMy by class I MHC molecules, followed by transport to the cell surface [11] .
Previously, we have identified an MHC dass, I H-2D hbinding peptide, HPVJ6 E7 49-57 {RAHYNIVTF), that elicited CTL responses in C57BU6 (B6) (H-2 h ) mice f 12]. Vaccination with synthetic peptide E7 49-57. either mixed with 1FA [12] or loaded on dendritic cells [32|. specificaMy prevented tumor formation by HPVKvtransformed Eifi mouse embryo cells (MEC) (C3 cells). Protection was associated with expansion of peptide-specific CTL. which upon stimulation from memory cells, were capable of lysing C3 cells in vitro [12] , presumably as the result of specific recognition of peptide E7 49-57 presented by class t MHC H-2D" molecules on the tumor cell membrane. Therefore, CTL raised against synthetic peptide E749-57 should be'able to rccogni/e naturally processed E7 49-57 peptide expressed: on HPV 16-transformed C3 cells and cure established C3 tumors when injected in tumorbeartng B6 mice.
In this study, we describe ïhe generation and characterization of a stable CTL line raised against synthetic peplidc E7 49-57. This CTL line specifically recognizes E7 4^-57 as a naturally processed peptide on HPV]6-transf:>nned C3 ce3ls and eradicates established O tumors in Bn nude mice, in addition, we show that OTL epitope E7 49-57 is immuno-subdominantJy expressed on C3 cells, inasmuch as CTL raised against C3 cells recognize another naluralK' processed; peptide. The data prestrnled in this study are the first esampJes of CTL-based immunotherapy against established HPVI6-induced tumors, supporting the thought that T cells are involved in the control of cervical cancer. Furthermore, our data stress the feasibility of generating tumor-specific CTL againsl epitopes of choice, in particular subdomrnant epiiopes, offered as synthetic peptides. ;i| O: HPVId/EJriis-trsmliH-med B6 MKC. h) Xhoc.l: Ad5 Ht-tnitisfntmed B6 MEC c) pS: HPVIMrjnsfarnKd Bh M EC. dj Effector li> target ratio. e) Percentage specific lysis. The ex peri mem shown is :i representative of ik independent exceeded ill 'ii»n1' the c;ilciiliUcd m CM n percentage specific lysis, which is depicted.
Eür.J
s. SDof iriplit merited with HCS, antibiotics and 2-ME. as described [12] . CTL line FaO wa-% made by immunizing Bh mice s,c. with 11)0 ug synlhetic H7 4 ü -57~ peptide mixed with I FA [12] . After 14 days. T cell-enriched spleen cells [15] 
Mice and aduptive transfer
T cell-deficient Bft nude mice (Bolmholtyard. Ry. Denmark}, held under specific iiathogen-free conditions ;ii TNO-PG {Leiden. The Netherlands), were inoculated s.e. each with 5 x id" O cells at the right Hank. When tumors were about 200 mm', therapy was started via adoptive transfer of 25 x 10" CTL injected i.v. in the tail vein or intFaturnorally (i.t.) directly into the tumor in 300 |d or 50 )it ceil suspension, respectively. This was repeated weekly for 3 weeks and combined with s.c. administration of HI' IU rlL-2 in IFA an the left flank. THe same amount of 1L-2 was also given every .Vd day alïer CTL injection. . In titration experimems, the affinity of FaC3 for its cognate peptide was lost between JO and l pM (daïa not shown), which is comparable wilh other known murine CTL clones [18, 22] .
Qay-t attar aten of CTL trMtm«n! (Fig. 2) . In the mice receiving IL-2 s.c. only, six out of six (umors grew progressively (data not shown),
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Peptide-induced CTL against a subdominanl epikipe eradicate lumors 2M1
This was also observed in each of four mice that were treated with CTL clone 01 i.t. plus LL-2 s.c. (Fig. 2) . The latter combination is known to eradicate AdS-induced tumors ir B6 nude mice [18] , Although a turnor growth delay was observed in four of six mice, only one of six mice was cured from its C3 tumor following FaC3 i.v. plus 1L-2 s.c. administration (data not shown).
Discussion
We have shown that CTL induced against synthetic peptides representing a suhdomirianl epitope recognize the naturally processed counterparts on turnor cells. CTL line FaC3 eradicated C3 tumors in six out of six mice that received FaC3 i.t., whereas after i.v. administration eradication was observed in only one of six mice. Possibly, when injected i.v. under the conditions use<5, the number of FaC3 actually arriving at the tumor site was too low to cope with this fast-growing tumor. Only when iargc numbers of FaC3 were injected directly into the C3 tumor could an adequate E/T radio eould be reached in vivo, resulting in tumor destruction. Interestingly, the tumor size of the one mouse that was cured from its tumor after i.v. FaC3 administration, was the smallest of all CTLtreated lumors at the start of treatment (60 mnv). Further experiments are needed to determine whclher tumor size is an important factor leading to failure or success of CTL therapy. Alternatively, the homing properties of FaC3 may not be of the same quality as those of previously reported CTL clones that were abïe to eradicate tumors efficiently upon i.v. infusion |J3, 18, 28], However, absence of homing is unlikeiy, since CTL with exactly ihe same specificity as FaC3 can he grown from C3 tumors treated i.v. with FaC3 (preliminary results).
The results presented in this study show, for the first time. that HPVlf» E7-specific CTL are directly responsible for the disappearance of HPV16-induced tumor tissue. In another study in mice (C3H), although CTL specificity was not determined, it was suggested that HPVI6 E7 acts as a tumor rejection antigen for CTL }2 U |. Our data are also in agreement with studies showing that a correlation exists between prevalence and progression of HPV (16) Transplantation tolerance induced by antigen pretreatment and depleting anti-CD4 antibody depends on CD4* T cell regulation during the induction phase of the response Adult mice pretrealed with do n or-spec i fie transfusion and depleting anti-CD4 antibody 28 days before transplant accept fuily allogeneic heart grafts and become specifically tolerant without further treatment. The induction of tolerance in this model is not simply a function of CD4* T cell ablation, hut appears to depend on residual CD4* T cells which escape depletion and engage donor aHoanligen during a transient period of antibody blockade. To test the hypothesis that these CD4* T cells might be responsible for regulating immune responses toward the graft, mice were reconstituted with naive recipient Leukocytes at various times after pretreatment. Reconstitution either shortly after pretreatment or shortly after transplant had little effect on graft survival. However, when pretreated mice were given an additional dose of depleting anti-CD4 antibody at the time of transplant to target putative regulatory cells, naive leukocytes were able to cause acute graft rejection. These data suggest that in clinical transplantation specific T cell regulation might develop following pretrcatment with antigen and non-depleting anti-CD-I antibodies. Such an approach could provide donor-specific unresponsive r ess prior to transplant without the risks associated with sustained CD4 f T cell depletion.
l liitrn.liKïimi CD4 h T cells play a pivotal role in graft rejection and the breakdown of self-tolerance in the development of autoimmunity. A large number of experimental models h;tve demonstrated that monoclonal antibodies which target this T cell suhset can prolong allograft survival or inhibit the onset of autoimmune disease [ 1-1(3}. In view of this, anli-CD4 antibodies arc attracting increasing attention as clinicai Therapeutic agents . hui if these reagents are to be used lo maximum effect in man, it will be importani to establish their precise mode of action.
In murine models, impressive graft prolongation can be achieved using pcri-opcrativc administration of antibodies which deplete CD4' T cells, hut in clinical transplantation there may be a reluctance to use such antibodies at the time of transplan! because the depletion they cause is profound and long- 
Median survival
Kej words: Tolerance / Anti-CD4 antibody /Transplantatio and can be maintained by repeated challenge with antigen alone; no further antibody treatment is required. We have translated this approach into a strategy for the induction of tolerance to alloantigen in which recipient mice are pretreated with a donor-specific blood transfusion (DST) under ihe cover of a depleting anti-CD4 antibody [19. 20) . This pretreatment regimen leads to indefinite cardiac allograft survival in the majority of recipients and is independent of any further immunosuppressive therapy. Graft prolongation is donor specific and leads to operational tolerance in the Jong-term, in that animals with surviving heart grafts accept donor specific skin grafts but reject those from a third party J20). We have investigated the mechanisms responsible for aUograft survival in this model and demonstrate that the induction of tolerance depends on active immune regulation mediated by CD4 J T cells. Our observations support conclusions which could have fin important impact on the way in which the powerful immunosuppressive effects of anti-CD4 antibodies may he exploited in clinical transplantation.
Materials and methods

Mice
Mice (C3H/He: H-2 k and C57BL/K); B]fl. H-2 I% ) were obtained from Harlan-Olac, Bicester, GR or the National institute for Medical Research. Harrow, GB-
Anti-CD4anlibod>
The hybridoma YTA 3.1.2 [21] (kindly provided by Prof. H. Waldmann). produces an lgG2b rat anti-mouse CD4 antibody which was prepared as ascites in (LOU x DA)F, rats and purified by ammonium sulfale precipitation followed by ion-exchange chromatography. Antibody purily
